2024 |
Bland A, Chuah E, Meere W, Ford TJ, 'Targeted Therapies for Microvascular Disease', Cardiology Clinics, 42 137-145 (2024) [C1]
|
|
Nova |
2024 |
Bland A, Chuah E, Meere W, Ford TJ, 'Targeted Therapies for Microvascular Disease', Heart Failure Clinics, 20 91-99 (2024) [C1]
|
|
Nova |
2024 |
Jeyaprakash P, Mikhail P, Ford TJ, Pathan F, Berry C, Negishi K, 'Index of Microcirculatory Resistance to predict microvascular obstruction in STEMI: A systematic review and meta-analysis', Catheterization and Cardiovascular Interventions, 103 249-259 (2024) [C1]
Background: Microvascular obstruction (MVO) is an independent predictor of adverse cardiac events after ST-elevation myocardial infarction (STEMI). The Index of Microcirculatory R... [more]
Background: Microvascular obstruction (MVO) is an independent predictor of adverse cardiac events after ST-elevation myocardial infarction (STEMI). The Index of Microcirculatory Resistance (IMR) may be a useful marker of MVO, which could simplify the care pathway without the need for Cardiac Magnetic Resonance (CMR). We assessed whether the IMR can predict MVO in STEMI patients. Methods and Results: We conducted a systematic review and meta-analysis, including articles where invasive IMR was performed post primary percutaneous coronary intervention (PCI) in addition to MVO assessment with cardiac MRI. We searched PubMed, Scopus, Embase, and Cochrane databases from inception until January 2023. Baseline characteristics, coronary physiology and cardiac MRI data were extracted by two independent reviewers. The random-effects model was used to pool the data. Among 15 articles identified, nine articles (n = 728, mean age 61, 81% male) contained IMR data stratified by MVO. Patients with MVO had a mean IMR of 41.2 [95%¿CI 32.4-50.4], compared to 25.3 [18.3-32.2] for those without. The difference in IMR between those with and without MVO was 15.1 [9.7-20.6]. Meta-regression analyses demonstrated a linear relationship between IMR and TIMI grade (ß = 0.69 [0.13-1.26]), as well as infarct size (ß = 1.18 [0.24-2.11]) or ejection fraction at 6 months (ß = -0.18 [-0.35 to -0.01]). Conclusion: In STEMI, patients with MVO had 15-unit higher IMR than those without. IMR also predicts key prognostic endpoints such as infarct size, MVO, and long-term systolic function.
|
|
Nova |
2024 |
Ford TJ, Redwood E, Chuah E, 'Coronary Sinus Reduction: Can Device-Based Therapy Improve Coronary Microvascular Function?', Circulation: Cardiovascular Interventions, 17 E013831 (2024)
|
|
|
2024 |
Sidik NP, Stanley B, Sykes R, Morrow AJ, Bradley CP, McDermott M, et al., 'Invasive Endotyping in Patients with Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial', Circulation, 149 7-23 (2024) [C1]
BACKGROUND: We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries. METHODS: Outpat... [more]
BACKGROUND: We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries. METHODS: Outpatients referred for coronary computed tomography angiography in 3 hospitals in the United Kingdom were prospectively screened. After coronary computed tomography angiography, patients with unobstructed coronary arteries, and who consented, underwent invasive endotyping. The diagnostic assessments included coronary angiography, fractional flow reserve (patient excluded if =0.80), and, for those without obstructive coronary artery disease, coronary flow reserve (abnormal <2.0), index of microvascular resistance (abnormal =25), and intracoronary infusion of acetylcholine (0.182, 1.82, and 18.2 µg/mL; 2 mL/min for 2 minutes) to assess for microvascular and coronary spasm. Participants were randomly assigned to disclosure of the results of the coronary function tests to the invasive cardiologist (intervention group) or nondisclosure (control group, blinded). In the control group, a diagnosis of vasomotor angina was based on medical history, noninvasive tests, and coronary angiography. The primary outcome was the between-group difference in the reclassification rate of the initial diagnosis on the basis of coronary computed tomography angiography versus the final diagnosis after invasive endotyping. The Seattle Angina Questionnaire summary score and Treatment Satisfaction Questionnaire for Medication were secondary outcomes. RESULTS: Of 322 eligible patients, 250 (77.6%) underwent invasive endotyping; 19 (7.6%) had obstructive coronary disease, 127 (55.0%) had microvascular angina, 27 (11.7%) had vasospastic angina, 17 (7.4%) had both, and 60 (26.0%) had no abnormality. A total of 231 patients (mean age, 55.7 years; 64.5% women) were randomly assigned and followed up (median duration, 19.9 [12.6-26.9] months). The clinician diagnosed vasomotor angina in 51 (44.3%) patients in the intervention group and in 55 (47.4%) patients in the control group. After randomization, patients in the intervention group were 4-fold (odds ratio, 4.05 [95% CI, 2.32-7.24]; P<0.001) more likely to be diagnosed with a coronary vasomotor disorder; the frequency of this diagnosis increased to 76.5%. The frequency of normal coronary function (ie, no vasomotor disorder) was not different between the groups before randomization (51.3% versus 50.9%) but was reduced in the intervention group after randomization (23.5% versus 50.9%, P<0.001). At 6 and 12 months, the Seattle Angina Questionnaire summary score in the intervention versus control groups was 59.2±24.2 (2.3±16.2 change from baseline) versus 60.4±23.9 (4.6±16.4 change) and 63.7±23.5 (4.7±14.7 change) versus 66.0±19.3 (7.9±17.1 change), respectively, and not different between groups (global P=0.36). Compared with the control group, global treatment satisfaction was higher in the intervention group at 12 months (69.9±22.8 versus 61.7±26.9, P=0.013). CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03477890.
|
|
Nova |
2023 |
Ohashi H, Collison D, Mizukami T, Didagelos M, Sakai K, Aetesam-ur-Rahman M, et al., 'Fractional Flow Reserve-Guided Stent Optimisation in Focal and Diffuse Coronary Artery Disease', Diagnostics, 13 (2023) [C1]
Assessing coronary physiology after stent implantation facilitates the optimisation of percutaneous coronary intervention (PCI). Coronary artery disease (CAD) patterns can be char... [more]
Assessing coronary physiology after stent implantation facilitates the optimisation of percutaneous coronary intervention (PCI). Coronary artery disease (CAD) patterns can be characterised by the pullback pressure gradient (PPG) index. The impact of focal vs. diffuse disease on physiology-guided incremental optimisation strategy (PIOS) is unknown. This is a sub-study of the TARGET-FFR randomized clinical trial (NCT03259815). The study protocol directed that optimisation be attempted for patients in the PIOS arm when post-PCI FFR was <0.90. Overall, 114 patients (n = 61 PIOS and 53 controls) with both pre-PCI fractional flow reserve (FFR) pullbacks and post-PCI FFR were included. A PPG = 0.74 defined focal CAD. The PPG correlated significantly with post-PCI FFR (r = 0.43; 95% CI 0.26 to 0.57; p-value < 0.001) and normalised delta FFR (r = 0.49; 95% CI 0.34 to 0.62; p-value < 0.001). PIOS was more frequently applied to vessels with diffuse CAD (6% focal vs. 42% diffuse; p-value = 0.006). In patients randomized to PIOS, those with focal disease achieved higher post-PCI FFR than patients with diffuse CAD (0.93 ± 0.05 vs. 0.83 ± 0.07, p < 0.001). There was a significant interaction between CAD patterns and the randomisation arm for post-PCI FFR (p-value for interaction = 0.004). Physiology-guided stent optimisation was applied more frequently to vessels with diffuse disease; however, patients with focal CAD at baseline achieved higher post-PCI FFR.
|
|
Nova |
2023 |
Casinader S, Easey K, Mikhail P, Said C, May A, Scott D, et al., '"Distal Radial First": Primary Access for Coronary Angiography and Interventions', HEART LUNG AND CIRCULATION, 32 e10-e11 (2023)
|
|
|
2023 |
Ferreira D, Hardy J, Meere W, Butel-Simoes L, McGee M, Whitehead N, et al., 'Safety and care of no fasting prior to catheterization laboratory procedures: a non-inferiority randomized control trial protocol (SCOFF trial)', European Heart Journal Open, 3 (2023)
Aims Cardiac catheterization procedures are typically performed with local anaesthetic and proceduralist guided sedation. Various fasting regimens are routinely implemented prior ... [more]
Aims Cardiac catheterization procedures are typically performed with local anaesthetic and proceduralist guided sedation. Various fasting regimens are routinely implemented prior to these procedures, noting the absence of prospective evidence, aiming to reduce aspiration risk. However, there are additional risks from fasting including patient discomfort, intravascular volume depletion, stimulus for neuro-cardiogenic syncope, glycaemic outcomes, and unnecessary fasting for delayed/can-celled procedures. Methods and results This is an investigator-initiated, multicentre, randomized trial with a prospective, open-label, blinded endpoint (PROBE) assessment based in New South Wales, Australia. Patients will be randomized 1:1 to fasting (6 h solid food and 2 h clear liquids) or to no fasting requirements. The primary outcome will be a composite of hypotension, hyperglycaemia, hypoglycaemia, and aspiration pneumonia. Secondary outcomes will include patient satisfaction, contrast-induced nephropathy, new intensive care admission, new non-invasive or invasive ventilation requirement post procedure, and 30-day mortality and readmission. Conclusions This is a pragmatic and clinically relevant randomised trial designed to compare fasting verse no fasting prior to cardiac catheterisation procedures. Routine fasting may not reduce peri-procedural adverse events in this setting.
|
|
|
2023 |
Collison D, Copt S, Mizukami T, Collet C, McLaren R, Didagelos M, et al., 'Angina after Percutaneous Coronary Intervention: Patient and Procedural Predictors', Circulation: Cardiovascular Interventions, 16 E012511 (2023) [C1]
Background: Twenty percent to 40% of patients are affected by angina after percutaneous coronary intervention (PCI), which is associated with anxiety, depression, impaired physica... [more]
Background: Twenty percent to 40% of patients are affected by angina after percutaneous coronary intervention (PCI), which is associated with anxiety, depression, impaired physical function, and reduced quality of life. Understanding patient and procedural factors associated with post-PCI angina may inform alternative approaches to treatment. Methods: Two hundred thirty patients undergoing PCI completed the Seattle Angina Questionnaire (SAQ-7) and European quality of life-5 dimension-5 level (EQ-5D-5L) questionnaires at baseline and 3 months post-PCI. Patients received blinded intracoronary physiology assessments before and after stenting. A post hoc analysis was performed to compare clinical and procedural characteristics among patients with and without post-PCI angina (defined by follow-up SAQ-angina frequency score <100). Results: Eighty-eight of 230 patients (38.3%) reported angina 3 months post-PCI and had a higher incidence of active smoking, atrial fibrillation, and history of previous myocardial infarction or PCI. Compared with patients with no angina at follow-up, they had lower baseline SAQ summary scores (69.48±24.12 versus 50.20±22.59, P<0.001) and EQ-5D-5L health index scores (0.84±0.15 versus 0.69±0.22, P<0.001). Pre-PCI fractional flow reserve (FFR) was lower among patients who had no post-PCI angina (0.56±0.15 versus 0.62±0.13, P=0.003). Percentage change in FFR after PCI had a moderate correlation with angina frequency score at follow-up (r=0.36, P<0.0001). Patients with post-PCI angina had less improvement in FFR (43.1±33.5% versus 67.0±50.7%, P<0.001). There were no between-group differences in post-PCI FFR, coronary flow reserve, or corrected index of microcirculatory resistance. Patients with post-PCI angina had lower SAQ-summary scores (64.01±22 versus 95.16±8.72, P=0.001) and EQ-5D-5L index scores (0.69±0.26 versus 0.91±0.17, P=0.001) at follow-up. Conclusions: Larger improvements in FFR following PCI were associated with less angina and better quality of life at follow-up. In patients with stable symptoms, intracoronary physiology assessment can inform expectations of angina relief and quality of life improvement after stenting and thereby help to determine the appropriateness of PCI. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03259815.
|
|
|
2023 |
Mikhail P, Ishak M, Spina R, Ford TJ, Kull A, 'PCI in Management of Acute Type A Aortic Dissection Involving the Left Main Coronary Artery', JACC-CARDIOVASCULAR INTERVENTIONS, 16 1939-1941 (2023)
|
|
Nova |
2023 |
Bland A, Chuah E, Meere W, Ford TJ, 'Targeted Therapies for Microvascular Disease', Interventional Cardiology Clinics, 12 131-139 (2023)
|
|
|
2023 |
Schindler TH, Fearon WF, Pelletier-Galarneau M, Ambrosio G, Sechtem U, Ruddy TD, et al., 'Myocardial Perfusion PET for the Detection and Reporting of Coronary Microvascular Dysfunction: A JACC: Cardiovascular Imaging Expert Panel Statement', JACC: Cardiovascular Imaging, 16 536-548 (2023) [C1]
Angina pectoris and dyspnea in patients with normal or nonobstructive coronary vessels remains a diagnostic challenge. Invasive coronary angiography may identify up to 60% of pati... [more]
Angina pectoris and dyspnea in patients with normal or nonobstructive coronary vessels remains a diagnostic challenge. Invasive coronary angiography may identify up to 60% of patients with nonobstructive coronary artery disease (CAD), of whom nearly two-thirds may, in fact, have coronary microvascular dysfunction (CMD) that may account for their symptoms. Positron emission tomography (PET) determined absolute quantitative myocardial blood flow (MBF) at rest and during hyperemic vasodilation with subsequent derivation of myocardial flow reserve (MFR) affords the noninvasive detection and delineation of CMD. Individualized or intensified medical therapies with nitrates, calcium-channel blockers, statins, angiotensin-converting enzyme inhibitors, angiotensin II type 1-receptor blockers, beta-blockers, ivabradine, or ranolazine may improve symptoms, quality of life, and outcome in these patients. Standardized diagnosis and reporting criteria for ischemic symptoms caused by CMD are critical for optimized and individualized treatment decisions in such patients. In this respect, it was proposed by the cardiovascular council leadership of the Society of Nuclear Medicine and Molecular Imaging to convene thoughtful leaders from around the world to serve as an independent expert panel to develop standardized diagnosis, nomenclature and nosology, and cardiac PET reporting criteria for CMD. This consensus document aims to provide an overview of the pathophysiology and clinical evidence of CMD, its invasive and noninvasive assessment, standardization of PET-determined MBFs and MFR into ¿classical¿ (predominantly related to hyperemic MBFs) and ¿endogen¿ (predominantly related to resting MBF) normal coronary microvascular function or CMD that may be critical for diagnosis of microvascular angina, subsequent patient care, and outcome of clinical CMD trials.
|
|
Nova |
2022 |
Sgueglia GA, Hassan A, Harb S, Ford TJ, Koliastasis L, Milkas A, et al., 'International Hand Function Study Following Distal Radial Access The RATATOUILLE Study', JACC-CARDIOVASCULAR INTERVENTIONS, 15 1205-1215 (2022) [C1]
|
|
|
2022 |
Rishad S, McEntegart M, Ford TJ, Di Mario C, Fajadet J, Lindsay M, et al., 'Comparative study of costs and resource utilization of rotational atherectomy versus intravascular lithotripsy for percutaneous coronary intervention', Minerva Cardiology and Angiology, 70 332-340 (2022) [C1]
BACKGROUND: Intravascular lithotripsy (IVL) is a novel alternative to rotational atherectomy (RA) for the modification of heavily calcified coronary stenoses prior to percutaneous... [more]
BACKGROUND: Intravascular lithotripsy (IVL) is a novel alternative to rotational atherectomy (RA) for the modification of heavily calcified coronary stenoses prior to percutaneous coronary intervention (PCI). We compare the real-world resource utilization and associated costs of PCI with adjunctive RA and IVL. METHODS: We compared the resource utilization, in-lab consumable costs and procedural data of 120 patients who underwent PCI with IVL from the Disrupt-CAD II study (NCT03328949) to 60 patients who underwent PCI with RA at the Golden Jubilee National Hospital, Glasgow, UK. The RA patients were consecutive and selected on the basis of being deemed suitable for IVL by an independent interventional cardiologist experienced in the use of both techniques. RESULTS: PCI with IVL was associated with significantly lower costs than PCI with RA (mean difference £ 398 [95% CI: £ 181-615]; P<0.001). Considering between-group differences, the IVL group used 4.02 fewer balloons (P<0.001), 3.03 fewer guidewires (P<0.001), 0.52 fewer guide catheters (P=0.001), 0.22 fewer guide extensions (P=0.004) and 1.03 fewer drug eluting stents (DES) (P<0.001) per case than the RA group. The IVL group had shorter procedural duration (mean difference 13.3 min [95% CI: 3.6-23.0]; P=0.008) but longer fluoroscopy times (mean difference 4.4 min [95% CI: 1.7-7.1]; P=0.002). CONCLUSIONS: In this indirect comparison, we found that the higher initial device costs of IVL may be offset by a lower overall resource utilization. Further research is required to confirm this, and future randomized trials should include a formal health economic analysis.
|
|
Nova |
2022 |
Collet C, Collison D, Mizukami T, McCartney P, Sonck J, Ford T, et al., 'Differential Improvement in Angina and Health-Related Quality of Life After PCI in Focal and Diffuse Coronary Artery Disease', JACC: Cardiovascular Interventions, 15 2506-2518 (2022) [C1]
Background: An increase in fractional flow reserve (FFR) after percutaneous coronary intervention (PCI) is associated with improvement in angina. Coronary artery disease (CAD) pat... [more]
Background: An increase in fractional flow reserve (FFR) after percutaneous coronary intervention (PCI) is associated with improvement in angina. Coronary artery disease (CAD) patterns (focal vs diffuse) influence the FFR change after stenting and may predict angina relief. Objectives: The aim of this study was to investigate the differential improvement in patient-reported outcomes after PCI in focal and diffuse CAD as defined by the pullback pressure gradient (PPG). Methods: This is a subanalysis of the TARGET-FFR (Trial of Angiography vs. pressure-Ratio-Guided Enhancement Techniques¿Fractional Flow Reserve) randomized clinical trial. The 7-item Seattle Angina Questionnaire (SAQ-7) was administered at baseline and 3 months after PCI. The PPG index was calculated from manual pre-PCI FFR pullbacks. The median PPG value was used to define focal and diffuse CAD. Residual angina was defined as an SAQ-7 score <100. Results: A total of 103 patients were analyzed. There were no differences in the baseline characteristics between patients with focal and diffuse CAD. Focal disease had larger increases in FFR after PCI than patients with diffuse disease (0.30 ± 0.14 vs 0.19 ± 0.12; P < 0.001). Patients with focal disease who underwent PCI for focal CAD had significantly higher SAQ-7 summary scores at follow-up than those with diffuse CAD (87.1 ± 20.3 vs 75.6 ± 24.4; mean difference = 11.5 [95% CI: 2.8-20.3]; P = 0.01). After PCI, residual angina was present in 39.8% but was significantly less in those with treated focal CAD (27.5% vs 51.9%; P = 0.020). Conclusions: Residual angina after PCI was almost twice as common in patients with a low PPG (diffuse disease), whereas patients with a high PPG (focal disease) reported greater improvement in angina and quality of life. The baseline pattern of CAD can predict the likelihood of angina relief. (Trial of Angiography vs. pressure-Ratio-Guided Enhancement Techniques¿Fractional Flow Reserve [TARGET-FFR]; NCT03259815)
|
|
|
2022 |
Kim SK, Wing-Lun E, Chandrasekhar J, Puri A, Burgess S, Ford TJ, et al., 'The Australian New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry - A Multi-Centre Cohort Study: Protocol, Background and Significance', HEART LUNG AND CIRCULATION, 31 1612-1618 (2022)
|
|
|
2022 |
Ford TJ, Adamson C, Morrow AJ, Rocchiccioli P, Collison D, McCartney PJ, et al., 'Coronary Artery Perforations: Glasgow Natural History Study of Covered Stent Coronary Interventions (GNOCCI) Study.', J Am Heart Assoc, 11 e024492 (2022) [C1]
|
|
Nova |
2022 |
Mikhail P, Howden N, Monjur M, Jeyaprakash P, Said C, Bland A, et al., 'Coronary perforation incidence, outcomes and temporal trends (COPIT): a systematic review and meta-analysis.', Open Heart, 9 (2022) [C1]
|
|
Nova |
2022 |
Ford TJ, Mikhail P, 'Acetylcholine (Re)challenge From Diagnosis to Targeted Therapy', JACC-CARDIOVASCULAR INTERVENTIONS, 15 76-79 (2022)
|
|
|
2021 |
Ford TJ, Howden N, '"Vessels of Vessels" Linking Coronary Imaging With Physiology in INOCA', JACC-CARDIOVASCULAR INTERVENTIONS, 14 619-622 (2021)
|
|
|
2021 |
Shimokawa H, Suda A, Takahashi J, Berry C, Camici PG, Crea F, et al., 'Clinical characteristics and prognosis of patients with microvascular angina: An international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group', European Heart Journal, 42 4592-4600 (2021) [C1]
Aims: To provide multi-national, multi-ethnic data on the clinical characteristics and prognosis of patients with microvascular angina (MVA). Methods and results: The Coronary Vas... [more]
Aims: To provide multi-national, multi-ethnic data on the clinical characteristics and prognosis of patients with microvascular angina (MVA). Methods and results: The Coronary Vasomotor Disorders International Study Group proposed the diagnostic criteria for MVA. We prospectively evaluated the clinical characteristics of patients according to these criteria and their prognosis. The primary endpoint was the composite of major cardiovascular events (MACE), verified by institutional investigators, which included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization due to heart failure or unstable angina. During the period from 1 July 2015 to 31 December 2018, 686 patients with MVA were registered from 14 institutes in 7 countries from 4 continents. Among them, 64% were female and the main ethnic groups were Caucasians (61%) and Asians (29%). During follow-up of a median of 398 days (IQR 365-744), 78 MACE occurred (6.4% in men vs. 8.6% in women, P = 0.19). Multivariable Cox proportional hazard analysis disclosed that hypertension and previous history of coronary artery disease (CAD), including acute coronary syndrome and stable angina pectoris, were independent predictors of MACE. There was no sex or ethnic difference in prognosis, although women had lower Seattle Angina Questionnaire scores than men (P < 0.05). Conclusions: This first international study provides novel evidence that MVA is an important health problem regardless of sex or ethnicity that a diagnosis of MVA portends a substantial risk for MACE associated with hypertension and previous history of CAD, and that women have a lower quality of life than men despite the comparable prognosis.
|
|
Nova |
2021 |
Collison D, Didagelos M, Aetesam-Ur-Rahman M, Copt S, McDade R, McCartney P, et al., 'Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)', European Heart Journal, 42 4656-4668 (2021) [C1]
Aims A fractional flow reserve (FFR) value =0.90 after percutaneous coronary intervention (PCI) is associated with a reduced risk of adverse cardiovascular events. TARGET-FFR is a... [more]
Aims A fractional flow reserve (FFR) value =0.90 after percutaneous coronary intervention (PCI) is associated with a reduced risk of adverse cardiovascular events. TARGET-FFR is an investigator-initiated, single-centre, randomized controlled trial to determine the feasibility and efficacy of a post-PCI FFR-guided optimization strategy vs. standard coronary angiography in achieving final post-PCI FFR values =0.90. Methods and results After angiographically guided PCI, patients were randomized 1:1 to receive a physiology-guided incremental optimization strategy (PIOS) or a blinded coronary physiology assessment (control group). The primary outcome was the proportion of patients with a final post-PCI FFR =0.90. Final FFR =0.80 was a prioritized secondary outcome. A total of 260 patients were randomized (131 to PIOS, 129 to control) and 68.1% of patients had an initial post-PCI FFR <0.90. In the PIOS group, 30.5% underwent further intervention (stent post-dilation and/or additional stenting). There was no significant difference in the primary endpoint of the proportion of patients with final post-PCI FFR =0.90 between groups (PIOS minus control 10%, 95% confidence interval -1.84 to 21.91, P = 0.099). The proportion of patients with a final FFR =0.80 was significantly reduced when compared with the angiography-guided control group (-11.2%, 95% confidence interval -21.87 to -0.35], P = 0.045). Conclusion Over two-thirds of patients had a physiologically suboptimal result after angiography-guided PCI. An FFR-guided optimization strategy did not significantly increase the proportion of patients with a final FFR =0.90, but did reduce the proportion of patients with a final FFR =0.80.
|
|
|
2021 |
Maznyczka AM, McCartney PJ, Oldroyd KG, Lindsay M, McEntegart M, Eteiba H, et al., 'Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction', CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 14 (2021) [C1]
|
|
Nova |
2021 |
Heggie R, Briggs A, Stanley B, Good R, Rocchiccioli P, McEntegart M, et al., 'Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial', International Journal of Cardiology, 337 44-51 (2021) [C1]
Aim: Coronary angiography is indicated in many patients with known or suspected angina for the investigation of coronary artery disease (CAD). However, up to half of patients with... [more]
Aim: Coronary angiography is indicated in many patients with known or suspected angina for the investigation of coronary artery disease (CAD). However, up to half of patients with symptoms of ischaemia have no obstructive coronary arteries (INOCA). This large subgroup includes patients with suspected microvascular angina (MVA) and/or vasospastic angina (VSA). Clinical guidelines relating to the management of patients with INOCA are limited. Uncertainty regarding the diagnosis of patients with INOCA presents a health economic challenge, both in terms of healthcare resource utilisation and of quality-of-life impact on patients. Methods: A cost-effectiveness analysis of the introduction of stratified medicine into the invasive management of INOCA, based on clinical and resource-use data obtained in the CorMicA trial, from a UK NHS perspective. The intervention included an invasive diagnostic procedure (IDP) of coronary vascular function during coronary angiography to define clinical endotypes to target with linked medical therapy. Outcomes of interest were mean total cost and QALY gain between treatment groups, and the incremental cost-effectiveness ratio. We undertook probabilistic sensitivity and scenario analyses. Results: The incremental cost per QALY gained at 12 months was £4500 (£2937, £33264). Compared with a willingness-to-pay (WTP) threshold of £20,000 per QALY, the use of the IDP test is cost-effective. At this WTP threshold there is a 96% probability of the IDP being cost-effective, based on the uncertainty described by bootstrap analysis. Conclusions: The burden of INOCA, particularly in women, is known to be significant. These findings provided new evidence to inform this unmet clinical need.
|
|
|
2021 |
Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al., 'Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction', JAMA Cardiology, 6 1130-1143 (2021) [C1]
Importance: Coronary artery disease (CAD) and coronary microvascular dysfunction (CMD) may contribute to the pathophysiologic characteristics of heart failure with preserved eject... [more]
Importance: Coronary artery disease (CAD) and coronary microvascular dysfunction (CMD) may contribute to the pathophysiologic characteristics of heart failure with preserved ejection fraction (HFpEF). However, the prevalence of CAD and CMD have not been systematically studied. Objective: To examine the prevalence of CAD and CMD in hospitalized patients with HFpEF. Design, Setting, and Participants: A total of 106 consecutive patients hospitalized with HFpEF were evaluated in this prospective, multicenter, cohort study conducted between January 2, 2017, and August 1, 2018; data analysis was performed from March 4 to September 6, 2019. Participants underwent coronary angiography with guidewire-based assessment of coronary flow reserve, index of microvascular resistance, and fractional flow reserve, followed by coronary vasoreactivity testing. Cardiac magnetic resonance imaging was performed with late gadolinium enhancement and assessment of extracellular volume. Myocardial perfusion was assessed qualitatively and semiquantitatively using the myocardial-perfusion reserve index. Main Outcomes and Measures: The prevalence of obstructive epicardial CAD, CMD, and myocardial ischemia, infarction, and fibrosis. Results: Of 106 participants enrolled (53 [50%] women; mean [SD] age, 72 [9] years), 75 had coronary angiography, 62 had assessment of coronary microvascular function, 41 underwent coronary vasoreactivity testing, and 52 received cardiac magnetic resonance imaging. Obstructive epicardial CAD was present in 38 of 75 participants (51%, 95% CI, 39%-62%); 19 of 38 (50%; 95% CI, 34%-66%) had no history of CAD. Endothelium-independent CMD (ie, coronary flow reserve <2.0 and/or index of microvascular resistance =25) was identified in 41 of 62 participants (66%; 95% CI, 53%-77%). Endothelium-dependent CMD (ie, abnormal coronary vasoreactivity) was identified in 10 of 41 participants (24%; 95% CI, 13%-40%). Overall, 45 of 53 participants (85%; 95% CI, 72%-92%) had evidence of CMD and 29 of 36 (81%; 95% CI, 64%-91%) of those without obstructive epicardial CAD had CMD. Cardiac magnetic resonance imaging findings included myocardial-perfusion reserve index less than or equal to 1.84 (ie, impaired global myocardial perfusion) in 29 of 41 patients (71%; 95% CI, 54%-83%), visual perfusion defect in 14 of 46 patients (30%; 95% CI, 19%-46%), ischemic late gadolinium enhancement (ie, myocardial infarction) in 14 of 52 patients (27%; 95% CI, 16%-41%), and extracellular volume greater than 30% (ie, diffuse myocardial fibrosis) in 20 of 48 patients (42%; 95% CI, 28%-56%). Patients with obstructive CAD had more adverse events during follow-up (28 [74%]) than those without obstructive CAD (17 [46%]). Conclusions and Relevance: In this cohort study, 91% of patients with HFpEF had evidence of epicardial CAD, CMD, or both. Of those without obstructive CAD, 81% had CMD. Obstructive epicardial CAD and CMD appear to be common and often unrecognized in hospitalized patients with HFpEF and may be therapeutic targets.
|
|
|
2021 |
Ferreira D, Mikhail P, McGee M, Boyle A, Sverdlov A, William M, et al., 'Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (Pressure-AF)', OPEN HEART, 8 (2021)
|
|
|
2021 |
Mikhail P, Rogers J, Forsyth C, Ford TJ, 'Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report', EUROPEAN HEART JOURNAL-CASE REPORTS, 5 (2021)
|
|
|
2020 |
Ford TJ, Khan A, Docherty KF, Jackson A, Morrow A, Sidik N, et al., 'Sex differences in procedural and clinical outcomes following rotational atherectomy', Catheterization and Cardiovascular Interventions, 95 232-241 (2020) [C1]
Aim: Evaluate sex differences in procedural net adverse clinical events and long-term outcomes following rotational atherectomy (RA). Methods and Results: From August 2010 to 2016... [more]
Aim: Evaluate sex differences in procedural net adverse clinical events and long-term outcomes following rotational atherectomy (RA). Methods and Results: From August 2010 to 2016, 765 consecutive patients undergoing RA PCI were followed up for a median of 4.7 years. 285 (37%) of subjects were female. Women were older (mean 76 years vs. 72 years; p <.001) and had more urgent procedures (64.6 vs. 47.3%; p <.001). Females received fewer radial procedures (75.1 vs. 85.1%; p <.001) and less intravascular imaging guidance (16.8 vs. 25.0%; p =.008). After propensity score adjustment, the primary endpoint of net adverse cardiac events (net adverse clinical events: all-cause death, myocardial infarction, stroke, target vessel revascularization plus any procedural complication) occurred more often in female patients (15.1 vs. 9.0%; adjusted OR 1.81 95% CI 1.04¿3.13; p =.037). This was driven by an increased risk of procedural complications rather than procedural major adverse cardiac events (MACE). Specifically, women were more likely to experience coronary dissection (4.6 vs. 1.3%; p =.008), cardiac tamponade (2.1 vs. 0.4%; p =.046) and significant bleeding (BARC =2: 5.3 vs. 2.3). Despite this, overall MACE-free survival was similar between males and females (adjusted HR 1.03; 95% CI 0.80¿1.34; p =.81). Procedural complications during RA were associated with almost double the incidence of MACE at long-term follow-up (HR 1.92; 95% CI 1.34¿2.77; p <.001). Conclusion: Women may be at greater risk of procedural complications following rotational atherectomy. These include periprocedural bleeding episodes and coronary perforation leading to cardiac tamponade. Despite this, the adjusted overall long-term survival free of major adverse cardiac events was similar between males and females.
|
|
|
2020 |
Morrow AJ, Ford TJ, McEntegart M, 'Chest pain with a cold', BMJ-BRITISH MEDICAL JOURNAL, 371 (2020)
|
|
|
2020 |
Ford TJ, Corcoran D, Padmanabhan S, Aman A, Rocchiccioli P, Good R, et al., 'Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.', European heart journal, 41 3239-3252 (2020) [C1]
|
|
Nova |
2020 |
Morrow AJ, Ford TJ, Mangion K, Kotecha T, Rakhit R, Galasko G, et al., 'Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial', AMERICAN HEART JOURNAL, 229 70-80 (2020)
|
|
|
2020 |
Monjur MR, Said CF, Bamford P, Parkinson M, Szirt R, Ford T, 'Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis', Open Heart, 7 (2020) [C1]
|
|
Nova |
2020 |
Cervantes-Arslanian A, Lau KHV, Anand P, Shulman JG, Ford T, Takahashi C, et al., 'Rapid Dissemination of Protocols for Managing Neurology Inpatients with COVID-19', ANNALS OF NEUROLOGY, 88 211-214 (2020)
|
|
|
2020 |
McCartney PJ, Eteiba H, Maznyczka AM, McEntegart M, Greenwood JP, Muir DF, et al., 'Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT', Efficacy and Mechanism Evaluation, 7 (2020) [C1]
|
|
|
2020 |
Suda A, Takahashi J, Beltrame JF, Berry C, Camici PG, Crea F, et al., 'International prospective cohort study of microvascular angina Rationale and design', IJC Heart and Vasculature, 31 (2020) [C1]
Background: Patients with signs and symptoms of myocardial ischemia and non-obstructive coronary artery disease (CAD) frequently have coronary functional abnormalities, including ... [more]
Background: Patients with signs and symptoms of myocardial ischemia and non-obstructive coronary artery disease (CAD) frequently have coronary functional abnormalities, including coronary microvascular dysfunction. Those with the latter are grouped under the term ¿microvascular angina¿ (MVA). Although diagnostic criteria exist for MVA, as recently proposed by our COVADIS (COronary VAsomotor Disorders International Study) group and the condition has been increasingly recognized in clinical practice, the clinical characteristics and long-term prognosis of MVA patients in the current era remain to be fully elucidated. Aims: In the present study, we aimed to prospectively assess the clinical characteristics and long-term prognosis of MVA subjects in the current era in an international, multicenter, observational, and prospective registry study. Methods: A total of 15 medical centers across 7 countries (USA, UK, Germany, Spain, Italy, Australia, and Japan) enrolled subjects fulfilling the COVADIS diagnostic criteria for MVA as follows; (1) signs and/or symptoms of myocardial ischemia, (2) absence of obstructive CAD, and (3) objective evidence of myocardial ischemia and/or coronary microvascular dysfunction. The primary endpoint was the composite of major cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization due to heart failure or unstable angina. Between July 2015 and December 2018, a total of 706 subjects with MVA (M/F 256/450, 61.1 ± 11.8 [SD] yrs.) were registered. Subjects will be followed for at least 1 year. The present study will provide important information regarding the clinical characteristics, management, and long-term prognosis of MVA patients in the current era.
|
|
|
2020 |
Sidik NP, McEntegart M, Roditi G, Ford TJ, McDermott M, Morrow A, et al., 'Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study', AMERICAN HEART JOURNAL, 221 48-59 (2020)
|
|
|
2020 |
McCartney PJ, Maznyczka AM, Eteiba H, McEntegart M, Oldroyd KG, Greenwood JP, et al., 'Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 75 1406-1421 (2020) [C1]
|
|
|
2020 |
Hennigan B, Berry C, Collison D, Corcoran D, Eteiba H, Good R, et al., 'Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial', HEART, 106 758-764 (2020) [C1]
|
|
|
2020 |
Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al., '1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA)', JACC-CARDIOVASCULAR INTERVENTIONS, 13 33-45 (2020) [C1]
|
|
|
2020 |
Ford TJ, Ong P, Sechtem U, Beltrame J, Camici PG, Crea F, et al., 'Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When', JACC: Cardiovascular Interventions, 13 1847-1864 (2020) [C1]
Ischemic heart disease secondary to coronary vascular dysfunction causes angina and impairs quality of life and prognosis. About one-half of patients with symptoms and signs of is... [more]
Ischemic heart disease secondary to coronary vascular dysfunction causes angina and impairs quality of life and prognosis. About one-half of patients with symptoms and signs of ischemia turn out not to have obstructive coronary artery disease, and coronary vascular dysfunction may be relevant. Adjunctive tests of coronary vasomotion include guidewire-based techniques with adenosine and reactivity testing, typically by intracoronary infusion of acetylcholine. The CorMicA (Coronary Microvascular Angina) trial provided evidence that routine management guided by an interventional diagnostic procedure and stratified therapy improves angina and quality of life in patients with angina but no obstructive coronary artery disease. In this paper, the COVADIS study group provide a comprehensive review of why, how, and when coronary vascular dysfunction should be assessed invasively. They discuss the rationale through a shared understanding of vascular pathophysiology and clinical evidence. They propose a consensus approach to how an interventional diagnostic procedure is performed with focus on practical aspects. Finally, the authors discuss the clinical scenarios in patients with stable and acute coronary syndromes in which measurement of coronary vascular function may be helpful for patient care.
|
|
Nova |
2020 |
Maznyczka AM, McCartney PJ, Eteiba H, Greenwood JP, Muir DF, Chowdhary S, et al., 'One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention The T-TIME Randomized Trial', CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 13 (2020)
|
|
|
2020 |
Fong LCW, Ford TJ, Costa BR, Juni P, Berry C, 'Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 9 (2020) [C1]
|
|
Nova |
2020 |
Ford TJ, Berry C, 'Angina: contemporary diagnosis and management', Heart (British Cardiac Society), 106 387-398 (2020) [C1]
|
|
Nova |
2019 |
Ubaid S, Ford TJ, Berry C, Wrigley B, Thomas M, Murray H, et al., 'Intravenous cangrelor vs oral ticagrelor in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous intervention: A randomised controlled trial', Clinical Medicine, 19 s128-s128 (2019)
|
|
|
2019 |
'ASSOCIATION OF PHYSICIANS OF GREAT BRITAIN AND IRELAND Annual General Meeting 28-29 March 2019 Abstracts', QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 112 724-742 (2019)
|
|
|
2019 |
Morrow A, Ford TJ, Brogan R, 'Incidence of acute bronchospasm during systemic adenosine administration for coronary angiography', JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 49 204-206 (2019)
|
|
|
2019 |
Adamson C, Rocchiccioli P, Brogan R, Berry C, Ford TJ, 'Post-operative myocardial infarction following aortic root surgery with coronary reimplantation: a case series treated with percutaneous coronary intervention', EUROPEAN HEART JOURNAL-CASE REPORTS, 3 (2019)
|
|
|
2019 |
McCartney PJ, Eteiba H, Maznyczka AM, McEntegart M, Greenwood JP, Muir DF, et al., 'Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction A Randomized Clinical Trial', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 321 56-68 (2019) [C1]
|
|
|
2019 |
Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N, et al., 'Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial', THROMBOSIS AND HAEMOSTASIS, 119 1171-1181 (2019) [C1]
|
|
|
2019 |
Maznyczka AM, Ford TJ, Oldroyd KG, 'Revascularisation and mechanical circulatory support in patients with ischaemic cardiogenic shock', HEART, 105 1364-1374 (2019)
|
|
|
2019 |
Ford TJ, Corcoran D, Sidik N, Oldroyd KG, Rocchiccioli P, McEntegart M, Berry C, 'MINOCA: Requirement for Definitive Diagnostic Work-Up', HEART LUNG AND CIRCULATION, 28 E4-E6 (2019)
|
|
|
2019 |
Ford TJ, Berry C, 'How to diagnose and manage angina without obstructive coronary artery disease: Lessons from the British heart foundation CorMicA trial', Interventional Cardiology: Reviews, Research, Resources, 14 76-82 (2019)
Patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (INOCA) present a diagnostic and therapeutic challenge. Microvascular and/or vasospasti... [more]
Patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (INOCA) present a diagnostic and therapeutic challenge. Microvascular and/or vasospastic angina are the two most common causes of INOCA; however, invasive coronary angiography lacks the sensitivity to diagnose these functional coronary disorders. In this article, the authors summarise the rationale for invasive testing in the absence of obstructive coronary disease, namely that correct treatment for angina patients starts with the correct diagnosis. They provide insights from the CORonary MICrovascular Angina (CorMicA) study, where an interventional diagnostic procedure was performed with linked medical therapy to improve patient health. Identification of these distinct disorders (microvascular angina, vasospastic angina or non-cardiac chest pain) is key for stratifying INOCA patients, allowing prognostic insights and better patient care with linked therapy based on contemporary guidelines. Finally, they propose a framework to diagnose and manage patients in this common clinical scenario.
|
|
|
2019 |
Ford TJ, Yii E, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al., 'Ischemia and No Obstructive Coronary Artery Disease Prevalence and Correlates of Coronary Vasomotion Disorders', CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 12 (2019) [C1]
|
|
|
2019 |
Berry C, Sidik N, Pereira AC, Ford TJ, Touyz RM, Kaski J-C, Hainsworth AH, 'Small-Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 8 (2019) [C1]
|
|
|
2018 |
Ford TJ, Rocchiccioli P, Good R, McEntegart M, Eteiba H, Watkins S, et al., 'Systemic microvascular dysfunction in microvascular and vasospastic angina', European Heart Journal, 39 4086-4097 (2018) [C1]
Aims Coronary microvascular dysfunction and/or vasospasm are potential causes of ischaemia in patients with no obstructive coronary artery disease (INOCA). We tested the hypothesi... [more]
Aims Coronary microvascular dysfunction and/or vasospasm are potential causes of ischaemia in patients with no obstructive coronary artery disease (INOCA). We tested the hypothesis that these patients also have functional abnormalities in peripheral small arteries. Methods and results Patients were prospectively enrolled and categorised as having microvascular angina (MVA), vasospastic angina (VSA) or normal control based on invasive coronary artery function tests incorporating probes of endothelial and endothelial-independent function (acetylcholine and adenosine). Gluteal biopsies of subcutaneous fat were performed in 81 subjects (62 years, 69% female, 59 MVA, 11 VSA, and 11 controls). Resistance arteries were dissected enabling study using wire myography. Maximum relaxation to ACh (endothelial function) was reduced in MVA vs. controls [median 77.6 vs. 98.7%; 95% confidence interval (CI) of difference 2.338%; P = 0.0047]. Endotheliumindependent relaxation [sodium nitroprusside (SNP)] was similar between all groups. The maximum contractile response to endothelin-1 (ET-1) was greater in MVA (median 121%) vs. controls (100%; 95% CI of median difference 4.745%, P = 0.015). Response to the thromboxane agonist, U46619, was also greater in MVA (143%) vs. controls (109%; 95% CI of difference 1357%, P = 0.003). Patients with VSA had similar abnormal patterns of peripheral vascular reactivity including reduced maximum relaxation to ACh (median 79.0% vs. 98.7%; P = 0.03) and increased response to constrictor agonists including ET-1 (median 125% vs. 100%; P = 0.02). In all groups, resistance arteries were 50-fold more sensitive to the constrictor effects of ET-1 compared with U46619. Conclusions Systemic microvascular abnormalities are common in patients with MVA and VSA. These mechanisms may involve ET-1 and were characterized by endothelial dysfunction and enhanced vasoconstriction.
|
|
|
2018 |
Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al., 'Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial', Journal of the American College of Cardiology, 72 2841-2855 (2018) [C1]
Background: Patients with angina symptoms and/or signs of ischemia but no obstructive coronary artery disease (INOCA) pose a diagnostic and therapeutic challenge. Objectives: The ... [more]
Background: Patients with angina symptoms and/or signs of ischemia but no obstructive coronary artery disease (INOCA) pose a diagnostic and therapeutic challenge. Objectives: The purpose of this study was to test whether an interventional diagnostic procedure (IDP) linked to stratified medicine improves health status in patients with INOCA. Methods: The authors conducted a randomized, controlled, blinded clinical trial of stratified medical therapy versus standard care in patients with angina. Patients with angina undergoing invasive coronary angiography (standard care) were recruited. Patients without obstructive CAD were immediately randomized 1:1 to the intervention group (stratified medical therapy) or the control group (standard care, IDP sham procedure). The IDP consisted of guidewire-based assessment of coronary flow reserve, index of microcirculatory resistance, fractional flow reserve, followed by vasoreactivity testing with acetylcholine. The primary endpoint was the mean difference in angina severity at 6 months (assessed by the Seattle Angina Questionnaire summary score). Results: A total of 391 patients were enrolled between November 25, 2016, and November 12, 2017. Coronary angiography revealed obstructive disease in 206 (53.7%). One hundred fifty-one (39%) patients without angiographically obstructive CAD were randomized (n = 76 intervention group; n = 75 blinded control group). The intervention resulted in a mean improvement of 11.7 U in the Seattle Angina Questionnaire summary score at 6 months (95% confidence interval [CI]: 5.0 to 18.4; p = 0.001). In addition, the intervention led to improvements in the mean quality-of-life score (EQ-5D index 0.10 U; 95% CI: 0.01 to 0.18; p = 0.024) and visual analogue score (14.5 U; 95% CI: 7.8 to 21.3; p < 0.001). There were no differences in major adverse cardiac events at the 6-month follow-up (2.6% controls vs. 2.6% intervention; p = 1.00). Conclusions: Coronary angiography often fails to identify patients with vasospastic and/or microvascular angina. Stratified medical therapy, including an IDP with linked medical therapy, is routinely feasible and improves angina in patients with no obstructive CAD. (CORonary MICrovascular Angina [CorMicA]; NCT03193294)
|
|
|
2018 |
Corcoran D, Ford TJ, Hsu L-Y, Chiribiri A, Orchard V, Mangion K, et al., 'Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study', OPEN HEART, 5 (2018)
|
|
|
2018 |
Ford TJ, Corcoran D, Oldroyd KG, McEntegart M, Rocchiccioli P, Watkins S, et al., 'Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial', AMERICAN HEART JOURNAL, 201 86-94 (2018)
|
|
|
2018 |
Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin S-S, et al., 'Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine', NEW ENGLAND JOURNAL OF MEDICINE, 378 603-614 (2018) [C1]
|
|
|
2018 |
Ford TJ, 'Coronary physiology and prognosis - What does pressure-bounded coronary flow reserve add?', INTERNATIONAL JOURNAL OF CARDIOLOGY, 261 32-34 (2018)
|
|
|
2018 |
Ford TJ, Corcoran D, Sidik N, McEntegart M, Berry C, 'Coronary Microvascular Dysfunction Assessment of Both Structure and Function', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 72 584-586 (2018)
|
|
|
2018 |
Ford TJ, Corcoran D, Berry C, 'Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need', HEART, 104 284-292 (2018) [C1]
|
|
|
2018 |
Ford TJ, Nguyen K, Brassil J, Kushwaha V, Friedman D, Allan R, et al., 'Balloon Aortic Valvuloplasty in the Transcatheter Valve Era: Single Centre Indications and Early Safety Data in a High Risk Population', HEART LUNG AND CIRCULATION, 27 595-600 (2018) [C1]
|
|
|
2018 |
Ford TJ, McEntegart M, Berry C, Oldroyd KG, 'Arterial Access for Invasive Coronary Angiography: The 'Left Backhander'', HEART LUNG AND CIRCULATION, 27 E98-E99 (2018)
|
|
|
2018 |
Ford TJ, Rocchiccioli P, 'SPOT DIAGNOSIS A keen eye for risk', BMJ-BRITISH MEDICAL JOURNAL, 360 (2018)
|
|
|
2018 |
Ford TJ, McCartney P, Corcoran D, Collison D, Hennigan B, McEntegart M, et al., 'Single- Versus 2-Stent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis of Randomized Trials With Long-Term Follow-up', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7 (2018) [C1]
|
|
|
2017 |
Ford TJ, Corcoran D, Berry C, 'Coronary artery disease: physiology and prognosis', EUROPEAN HEART JOURNAL, 38 1990-1992 (2017)
|
|
|
2017 |
Roy JR, Sun P, Ison G, Prasan AM, Ford T, Hopkins A, et al., 'Selective anti-scatter grid removal during coronary angiography and PCI: a simple and safe technique for radiation reduction', INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 33 771-778 (2017) [C1]
|
|
|
2017 |
Ford TJ, Berry C, De Bruyne B, Yong ASC, Barlis P, Fearon WF, Ng MKC, 'Physiological Predictors of Acute Coronary Syndromes Emerging Insights From the Plaque to the Vulnerable Patient', JACC-CARDIOVASCULAR INTERVENTIONS, 10 2539-2547 (2017)
|
|
|
2016 |
Ford T, Rees D, 'Patent ductus arteriosus illuminating an old eponym', BMJ-BRITISH MEDICAL JOURNAL, 353 (2016)
|
|
|
2015 |
Robaei D, Ford T, Ooi S-Y, 'Ankyrin-B Syndrome: A Case of Sinus Node Dysfunction, Atrial Fibrillation and Prolonged QT in a Young Adult', Heart Lung and Circulation, 24 E31-E34 (2015)
|
|
|
2014 |
Ford TJ, Fong MW, Cheah BC, Alexopolous C, 'Pulmonary hypertension and hepatic encephalopathy: lethal complications of Rendu-Osler-Weber disease.', J R Coll Physicians Edinb, 44 126-129 (2014)
|
|
|
2013 |
Ford TJ, 'An ECG that changed in a febrile patient (vol 346, f585, 2013)', BMJ-BRITISH MEDICAL JOURNAL, 346 (2013)
|
|
|
2013 |
Ford TJ, Cranney G, Li A, 'An ECG that changed in a febrile patient', BMJ-BRITISH MEDICAL JOURNAL, 346 (2013)
|
|
|
2012 |
Werth AJ, Ford TJ, 'Abdominal fat pads act as control surfaces in lieu of dorsal fins in the beluga (Delphinapterus)', MARINE MAMMAL SCIENCE, 28 E516-E527 (2012)
|
|
|
2010 |
Ford T, Whitworth C, Dhaun N, 'Minerva', BMJ, 340 c2887 (2010)
|
|
|
2008 |
Ford TJ, Dillon JF, 'Minocycline hepatitis', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 20 796-799 (2008)
|
|
|
2007 |
Camilleri M, Vazquez-Roque MI, Burton D, Ford T, Mckinzie S, Zinsmeister AR, 'Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans', NEUROGASTROENTEROLOGY AND MOTILITY, 19 30-38 (2007)
|
|
|
1992 |
FORD TJ, KRAUS SD, 'A RETE IN THE RIGHT WHALE', NATURE, 359 680-680 (1992)
|
|
|